Radiation dose from human platelets labelled with indium 111.

Area of Science:

• Nuclear Medicine
• Radiopharmacology
• Medical Imaging

Background:

• Platelet kinetics studies are crucial for understanding various hematological and cardiovascular conditions.
• Accurate assessment of radiation dose from radiopharmaceuticals is essential for patient safety.

Purpose of the Study:

• To determine the biological distribution of Indium-111 (111In)-labelled platelets in healthy individuals.
• To quantify the organ radiation dose associated with 111In-labelled platelet administration.
• To evaluate the safety of 111In as a labelling agent for platelet kinetic studies.

Main Methods:

• Whole-body counting was employed to track the distribution of 111In-labelled platelets.
• Scintillation-camera computer-assisted imaging provided detailed visualization of radiopharmaceutical distribution.
• Organ-specific radiation doses were calculated based on biodistribution data.

Main Results:

• The spleen received the highest radiation dose (7.4 mGy/MBq), followed by the liver (0.97 mGy/MBq).
• Whole-body radiation dose was 0.25 mGy/MBq.
• Gonad radiation doses were 0.14 mGy/MBq for males and 0.22 mGy/MBq for females.

Conclusions:

• Radiation doses from 111In-labelled platelets are within acceptable safety limits.
• Indium-111 is confirmed as a safe and effective labelling agent for studying platelet kinetics.
• The biodistribution and dosimetry data support the continued use of 111In-labelled platelets in clinical research.